Pages that link to "Q37227301"
Jump to navigation
Jump to search
The following pages link to Molecular engineering and design of therapeutic antibodies (Q37227301):
Displaying 50 items.
- Therapeutic antibodies, vaccines and antibodyomes (Q24599662) (← links)
- mAbs: a business perspective (Q24653360) (← links)
- Challenges and opportunities for non-antibody scaffold drugs (Q26781607) (← links)
- Challenges in Antibody Development against Tn and Sialyl-Tn Antigens (Q26798183) (← links)
- Atypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural Analysis (Q27677883) (← links)
- An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations (Q27685255) (← links)
- Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" mice (Q28749033) (← links)
- Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? (Q30385673) (← links)
- In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes (Q30891417) (← links)
- Progress towards recombinant anti-infective antibodies (Q33568256) (← links)
- Design and applications of bispecific heterodimers: molecular imaging and beyond (Q33732587) (← links)
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions (Q33733443) (← links)
- Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting (Q33740415) (← links)
- Beyond natural antibodies: the power of in vitro display technologies (Q33841864) (← links)
- Phage display and molecular imaging: expanding fields of vision in living subjects (Q33849788) (← links)
- Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. (Q33911461) (← links)
- Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors (Q33936717) (← links)
- Have we overestimated the benefit of human(ized) antibodies? (Q34142714) (← links)
- Introduction to current and future protein therapeutics: a protein engineering perspective (Q34168363) (← links)
- Engineered Fc based antibody domains and fragments as novel scaffolds (Q34289289) (← links)
- The characterization and quantitation of glycomic changes in CHO cells during a bioreactor campaign (Q34323725) (← links)
- Prediction and analysis of antibody amyloidogenesis from sequences (Q34544805) (← links)
- Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice (Q34555580) (← links)
- Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain (Q34724092) (← links)
- Clinical Ramifications of the MHC Family Fc Receptor FcRn (Q34754673) (← links)
- Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing (Q34772017) (← links)
- Development of Next-Generation Peptide Binders Using In vitro Display Technologies and Their Potential Applications (Q34892359) (← links)
- Selecting an appropriate method for expressing a recombinant protein (Q35011411) (← links)
- Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations (Q35013284) (← links)
- An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum (Q35077677) (← links)
- pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling (Q35080330) (← links)
- Characterization and screening of IgG binding to the neonatal Fc receptor (Q35163945) (← links)
- Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb (Q35765208) (← links)
- Understanding differences between synthetic and natural antibodies can help improve antibody engineering (Q35864868) (← links)
- Therapeutic antibodies against cancer (Q35908498) (← links)
- Selection and characterization of the novel anti-human PD-1 FV78 antibody from a targeted epitope mammalian cell-displayed antibody library. (Q36097041) (← links)
- Monoclonal antibodies and toxins--a perspective on function and isotype (Q36099489) (← links)
- A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. (Q36211427) (← links)
- Nanocell targeting using engineered bispecific antibodies. (Q36211456) (← links)
- Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes (Q36257660) (← links)
- The immunologic functions of the neonatal Fc receptor for IgG (Q36542347) (← links)
- Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas (Q36775313) (← links)
- Novel human antibody therapeutics: the age of the Umabs (Q37243228) (← links)
- How can we improve antibody-based cancer therapy? (Q37273461) (← links)
- A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity (Q37496579) (← links)
- Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein (Q37519151) (← links)
- Development of biosimilars--pharmacokinetic and pharmacodynamic considerations (Q37676066) (← links)
- The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases. (Q37706192) (← links)
- The safety and side effects of monoclonal antibodies (Q37715703) (← links)
- Therapeutic antibodies for autoimmunity and inflammation (Q37736260) (← links)